S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

PRA Health Sciences Stock Price, Forecast & Analysis (NASDAQ:PRAH)

$100.60
+0.43 (+0.43 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$99.16
Now: $100.60
$100.70
50-Day Range
$93.39
MA: $98.91
$106.65
52-Week Range
$82.12
Now: $100.60
$121.98
Volume248,639 shs
Average Volume536,103 shs
Market Capitalization$6.36 billion
P/E Ratio25.60
Dividend YieldN/A
Beta1.11
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.87 billion
Cash Flow$5.89 per share
Book Value$14.97 per share

Profitability

Net Income$153.90 million

Miscellaneous

Employees16,400
Market Cap$6.36 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.


PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) issued its earnings results on Wednesday, October, 30th. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.03. The medical research company earned $780.70 million during the quarter, compared to analysts' expectations of $771.64 million. PRA Health Sciences had a return on equity of 27.73% and a net margin of 8.00%. PRA Health Sciences's quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.13 EPS. View PRA Health Sciences' Earnings History.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for PRA Health Sciences.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $5.07-$5.12 for the period, compared to the Thomson Reuters consensus estimate of $5.07. The company issued revenue guidance of $3.02-$3.10 billion, compared to the consensus revenue estimate of $3.06 billion.

What price target have analysts set for PRAH?

9 brokerages have issued 12-month price objectives for PRA Health Sciences' shares. Their forecasts range from $100.00 to $126.00. On average, they expect PRA Health Sciences' share price to reach $115.86 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

What is the consensus analysts' recommendation for PRA Health Sciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

Has PRA Health Sciences been receiving favorable news coverage?

Media headlines about PRAH stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for PRA Health Sciences.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Paypal (PYPL), Lam Research (LRCX), Veeva Systems (VEEV), Netflix (NFLX), Splunk (SPLK) and GrubHub (GRUB).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the folowing people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
  • Mr. Michael J. Bonello, Exec. VP, CFO & Corp. Sec. (Age 49)
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Eagle Asset Management Inc. (1.12%), Massachusetts Financial Services Co. MA (0.98%), Carillon Tower Advisers Inc. (0.95%), Vaughan Nelson Investment Management L.P. (0.83%), Stephens Investment Management Group LLC (0.69%) and Artemis Investment Management LLP (0.36%). Company insiders that own PRA Health Sciences stock include David W Dockhorn, Fund Holdings LP Kkr, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Mackay Shields LLC, Sloane Robinson LLP, Icon Advisers Inc. Co., SG Americas Securities LLC, Meritage Portfolio Management, Bowling Portfolio Management LLC and Scout Investments Inc.. View Insider Buying and Selling for PRA Health Sciences.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Kornitzer Capital Management Inc. KS, Vaughan Nelson Investment Management L.P., Reilly Financial Advisors LLC, Tygh Capital Management Inc., Carillon Tower Advisers Inc., State of New Jersey Common Pension Fund D and California Public Employees Retirement System. View Insider Buying and Selling for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $100.60.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $6.36 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is http://www.prahs.com/.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel